Moneycontrol
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories

Dr Reddys Laboratories

BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Nov 21, 14:06
2417.15
139.85 (6.14%)
VOLUME 194,814
LIVE
NSE
Nov 21, 14:06
2421.00
146.55 (6.44%)
VOLUME 1,951,984
News on Dr Reddys Laboratories
Select Year: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Dr Reddy's gets EIR for Vizag plant, but inspection not closed

10.59 am | 21 Nov 2017 |  Source: PTI

It, however, said the US Food and Drug Administration has not closed the inspection and the manufacturing site's status remains unchanged....

Dr Reddy’s gains 9% on EIR from USFDA for Vizag facility, but inspection still on 

10.57 am | 21 Nov 2017 |  Source: Moneycontrol.com

The company has received the establishment inspection (EIR) report from USFDA for formulations manufacturing facility at Duvvada, Vishakhapatnam....

Dr Reddy Laboratories receives EIR fro mUSFDA

10.43 am | 21 Nov 2017 |  Source: Moneycontrol.com

Dr Reddy Laboratories has received the establishment inspection report from USFDA for formulations manufacturing facility at Duvvada, Vishakhapatnam....

Prescient messages about Indian companies circulate in WhatsApp groups

11.50 am | 16 Nov 2017 |  Source: Reuters

Dr. Reddy’s was going to report a loss, according to the message on the “Market Chatter” group, which was posted on July 24 from a mobile phone ...

Dr Reddy’s Laboratories launches anti-cancer drug in US market

3.21 pm | 14 Nov 2017 |  Source: PTI

According to a statement issued by the city-based drug maker, its generic version of the injection is available in single-dose, 20 ml flint vials cont...

Dr Reddy's Laboratories launched Clofarabine injection in US market

1.17 pm | 14 Nov 2017 |  Source: Moneycontrol.com

Dr Reddy's Laboratories has launched Clofarabine Injection, a therapeutic equivalent generic version of Clolar injection in the US Market, approve...

News highlights: Amit Shah confident of BJP winning 150 seats in Gujarat Assembly election

7.11 am | 14 Nov 2017 |  Source: Moneycontrol.com

Here’s wishing all our readers a Happy Children’s Day. This blog will keep track of key global and local developments impacting business and marke...

Buy Dr.Reddy’s Laboratories; target of Rs 3450: Dolat Capital

4.15 pm | 13 Nov 2017 |  Source: Moneycontrol.com

Dolat Capital is bullish on Dr.Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 3450 in its research report da...

Buy Music Broadcast; target of Rs 450: Dolat Capital

4.13 pm | 13 Nov 2017 |  Source: Moneycontrol.com

Dolat Capital is bullish on Music Broadcast has recommended buy rating on the stock with a target price of Rs 450 in its research report dated Novembe...

Dr Reddy's launches generic cancer drug in Canada

9.25 pm | 02 Nov 2017 |  Source: PTI

The company's product, which is a generic equivalent of Vidaza, has been approved by Health Canada, Dr Reddy's Laboratories said in a statemen...

US states look to widen price fixing probe into Dr Reddy’s, Sun Pharma & others

3.14 pm | 02 Nov 2017 |  Source: Moneycontrol.com

This was in addition to the previous lawsuit filed against two other Indian drug makers Heritage Pharmaceuticals a part of Emcure, and Aurobindo Pharm...

DRL, Sun Pharma, Glenmark among 18 under US lens on price fixing complaint

1.57 pm | 02 Nov 2017 |  Source: PTI

An official statement issued by Attorney General (AG) of Washington State, Bob Ferguson, yesterday said AGs of 45 other states, along with him, approa...

Accumulate Dr Reddy’s Lab; target of Rs 2680: KR Choksey

4.52 pm | 01 Nov 2017 |  Source: Moneycontrol.com

KR Choksey recommended accumulate rating on Dr Reddy’s with a target price of Rs 2680 in its research report dated November 01, 2017....

Dr Reddy's falls 3% post Q2 results; brokerages remain mixed

12.48 pm | 01 Nov 2017 |  Source: Moneycontrol.com

Brokerage were mixed on the results, with some of them pinning hopes on approvals. A few also pointed out US business prospects for the firm....

News Live: Alternative mechanism set up for consolidation of public sector banks

7.06 am | 01 Nov 2017 |  Source: Moneycontrol.com

This blog will keep track of key global and local developments impacting business and markets through the day. Important local and global political de...

Dr Reddy's Labs Q2 profit falls 3% on lower US biz; operating income beats estimates 

11.38 am | 31 Oct 2017 |  Source: Moneycontrol.com

Operating profit for the quarter stood at Rs 690 crore with margin at 19.4 percent....

News Live: Core sector output of eight industries increases to 5.2% in September

6.59 am | 31 Oct 2017 |  Source: Moneycontrol.com

This blog will keep track of key global and local developments impacting business and markets through the day. Important local and global political de...

Dr Reddys Labs Q2 profit seen down 9% on continued pricing pressure in US 

5.47 pm | 30 Oct 2017 |  Source: CNBC-TV18

Consolidated revenue during the quarter is seen rising 3 percent year-on-year to Rs 3,684 crore due to restocking post GST, according to average of es...

Dr Reddy's Laboratories recalls Famotidine tablets from US market

2.45 pm | 20 Oct 2017 |  Source: PTI

According to a notification put up by the US Food and Drug Administration, the recall is being made under 'Class-III' classification, which is...

Dr Reddys Labs Q2 PAT seen up 4.7% YoY to Rs. 308.8 cr: Kotak

5.57 pm | 13 Oct 2017 |  Source: Moneycontrol.com

Net Sales are expected to increase by 5.6 percent Y-o-Y (up 14.2 percent Q-o-Q) to Rs. 3787.8 crore, according to Kotak....

1 2 3
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.